Demyelination and Remyelination Therapies in Neurodegeneration

Migration, Crosslink

📖

Demyelination and Remyelination Therapies in Neurodegeneration

active

wiki page Created: 2026-04-02T07:19:02 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-therapeutics-demyelination-remyelin

📖 Wiki Page

therapeutic2237 wordssynced 2026-04-02

Demyelination and Remyelination Therapies in Neurodegeneration[@g2022]

Overview

flowchart TD DEMYELINATION["DEMYELINATION"] -->|"involved in"| NEUROMYELITIS_OPTICA_SPECTRUM_["NEUROMYELITIS OPTICA SPECTRUM DISORDER"] DEMYELINATION["DEMYELINATION"] -->|"involved in"| MULTIPLE_SCLEROSIS["MULTIPLE SCLEROSIS"] DEMYELINATION["DEMYELINATION"] -->|"involved in"| MOGAD["MOGAD"] Demyelination["Demyelination"] -->|"causes"| Reduced_Signal_Conduction["Reduced Signal Conduction"] Demyelination["Demyelination"] -->|"biomarker for"| Multiple_Sclerosis["Multiple Sclerosis"] Demyelination["Demyelination"] -->|"contributes to"| Neuronal_Loss["Neuronal Loss"] Demyelination["Demyelination"] -->|"contributes to"| Postoperative_neurocognitive_d["Postoperative neurocognitive disorder"] DEMYELINATION["DEMYELINATION"] -->|"activates"| NEURON["NEURON"] DEMYELINATION["DEMYELINATION"] -->|"exacerbates"| REMYELINATION["REMYELINATION"] DEMYELINATION["DEMYELINATION"] -->|"activates"| OLIGODENDROCYTES["OLIGODENDROCYTES"] DEMYELINATION["DEMYELINATION"] -->|"associated with"| NEURON["NEURON"] DEMYELINATION["DEMYELINATION"] -->|"triggers"| NEURODEGENERATION["NEURODEGENERATION"] DEMYELINATION["DEMYELINATION"] -->|"causes"| TREM2["TREM2"] DEMYELINATION["DEMYELINATION"] -->|"interacts with"| NEUROINFLAMMATION["NEUROINFLAMMATION"] style demyelination fill:#4fc3f7,stroke:#333,color:#000

...

Demyelination and Remyelination Therapies in Neurodegeneration[@g2022]

Overview

Mermaid diagram (expand to render)

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Demyelination and Remyelination Therapies in Neurodegeneration</th>
</tr>
<tr>
<td class="label">Agent</td>
<td>Mechanism</td>
</tr>
<tr>
<td class="label">Lingo-1 antagonist (opicinumab)</td>
<td>Remove OPC inhibition</td>
</tr>
<tr>
<td class="label">PDGFRalpha agonists</td>
<td>OPC proliferation</td>
</tr>
<tr>
<td class="label">T3/T4 thyroid hormone</td>
<td>OPC differentiation</td>
</tr>
<tr>
<td class="label">Bexarotene</td>
<td>RXR agonist; promotes OPC maturation</td>
</tr>
<tr>
<td class="label">Miconazole</td>
<td>Enhances OPC maturation</td>
</tr>
<tr>
<td class="label">Rolipram</td>
<td>PDE4 inhibitor; cAMP elevation</td>
</tr>
<tr>
<td class="label">Parameter</td>
<td>Frequency</td>
</tr>
<tr>
<td class="label">MRI DTI</td>
<td>Every 6 months</td>
</tr>
<tr>
<td class="label">Serum B12</td>
<td>Every 3 months</td>
</tr>
<tr>
<td class="label">LFTs (if on minocycline)</td>
<td>Monthly</td>
</tr>
<tr>
<td class="label">Cognitive: Trail Making A/B</td>
<td>Every 3 months</td>
</tr>
</table>

White matter pathology and demyelination represent a convergent pathological feature across multiple neurodegenerative diseases, yet therapeutic approaches have remained largely disease-specific. This page synthesizes evidence for remyelination therapies across Alzheimer's disease (AD), Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS), corticobasal syndrome (CBS), progressive supranuclear palsy (PSP), frontotemporal dementia (FTD), and Huntington's disease (HD).

The cross-disease angle is particularly compelling: myelin integrity directly affects three critical physiological processes that are impaired across neurodegeneration:

Axonal energy supply — Oligodendrocytes provide metabolic support to axons through lactate shuttling

Saltatory conduction — Myelin enables rapid nerve impulse transmission through saltation

Neurovascular coupling — White matter integrity affects blood flow regulation and nutrient delivery

This mechanistic convergence suggests that remyelination strategies developed primarily in multiple sclerosis may have broader applicability to neurodegenerative conditions where myelin dysfunction contributes to disease progression.

Scientific Rationale

Myelin as Therapeutic Target Across Neurodegeneration

The traditional view of demyelination as a primary autoimmune phenomenon in multiple sclerosis has given way to recognition that myelin dysfunction occurs across diverse neurodegenerative conditions, often as a secondary or contributing pathology [1].

Alzheimer's Disease: White matter lesions are present in up to 60% of AD cases, with demyelination observed in postmortem studies [2]. Myelin breakdown products accumulate in AD brain, contributing to neuroinflammation. Oligodendrocyte precursor cells (OPCs) show reduced differentiation capacity in AD [3].

Parkinson's Disease: Demyelination occurs in the substantia nigra and white matter tracts. Myelin protein expression (MBP, PLP) is reduced in PD brains, and oligodendrocyte loss contributes to dopaminergic axonal dysfunction [4]. White matter hyperintensities on MRI correlate with disease severity and cognitive impairment.

Amyotrophic Lateral Sclerosis: CNS myelin disruption occurs in both sporadic and familial ALS. Oligodendrocyte dysfunction precedes motor neuron degeneration in SOD1 mouse models, and OPCs show impaired maturation. White matter tract degeneration is evident on diffusion tensor imaging.

Corticobasal Syndrome/PSP: These 4R-tauopathies show prominent white matter hyperintensities on MRI. Tau pathology directly affects oligodendrocytes, disrupting myelin production. Fractional anisotropy is reduced in major white matter tracts.

Frontotemporal Dementia: White matter degeneration occurs in both behavioral variant FTD and primary progressive aphasia variants. Myelin breakdown contributes to executive dysfunction and language deficits.

Huntington's Disease: White matter volume loss precedes clinical symptoms in HD gene carriers. Oligodendrocyte dysfunction contributes to disease progression, and myelin integrity correlates with cognitive performance.

Three Mechanisms Linking Myelin to Neurodegeneration

Axonal Energy Supply

Oligodendrocytes provide critical metabolic support to axons through the lactate shuttle—oligodendrocytes metabolize glucose and deliver lactate to axons via monocarboxylate transporters (MCT1, MCT4) [5]. This metabolic coupling is essential for long-distance axonal maintenance. When oligodendrocytes are dysfunctional, axons experience energy deprivation that leads to degeneration.

In AD, amyloid-beta and tau pathology disrupt oligodendrocyte metabolic function. In PD, alpha-synuclein accumulation in oligodendrocytes (incidental Lewy bodies) impairs their support function. In ALS, oligodendrocyte degeneration contributes to axonal energy failure in motor pathways.

Saltatory Conduction

Myelin enables saltatory conduction—action potentials jump betweenNodes of Ranvier, increasing conduction velocity by up to 50-fold while reducing metabolic costs. Demyelination forces continuous (non-saltatory) conduction, dramatically increasing energy requirements and rendering axons more vulnerable to degeneration.

White matter tracts connecting cortical and subcortical regions are essential for cognitive function. Disruption of saltatory conduction in frontostriatal pathways contributes to executive dysfunction in FTD and HD; in corticospinal tracts, it contributes to upper motor neuron signs in ALS and PSP.

Neurovascular Coupling

White matter contains a dense network of blood vessels, and myelin integrity is coupled to cerebrovascular health. Demyelination disrupts neurovascular coupling—the ability of blood flow to match metabolic demand—leading to chronic hypoperfusion and further white matter damage.

This mechanism is particularly relevant in vascular dementia and CADASIL, but also contributes to AD pathology where cerebrovascular dysfunction and white matter lesions co-occur.

Therapeutic Approaches

Pharmacological Remyelination Agents

Clemastine Fumarate

Mechanism: Clemastine is an antihistamine that promotes oligodendrocyte differentiation and myelination through antagonism of M3 muscarinic receptors, which releases OPCs from inhibition [6].

Clinical Evidence:

Phase 2 trial in multiple sclerosis (RESTORE) showed improved visual evoked potential latency, indicating reversal of demyelination
Demonstrated OPC differentiation in preclinical models
Generally well-tolerated at doses of 8-16 mg daily

Application to Neurodegeneration: While studied primarily in MS, clemastine's OPC-promoting mechanism is relevant to all neurodegenerative conditions where oligodendrocyte function is impaired. Preclinical evidence in AD and PD models supports exploration.

Dosing: 8-16 mg daily (split dosing to reduce sedation) Evidence Level: Phase 2 (MS) — preclinical for neurodegeneration Safety Profile: Generally safe; sedation, dry mouth reported

Opicinumab (Anti-LINGO-1)

Mechanism: LINGO-1 is a transmembrane protein expressed on OPCs that negatively regulates myelination. Opicinumab is a monoclonal antibody that blocks LINGO-1, removing this inhibitory signal [7].

Clinical Evidence:

RENEW trial in acute optic neuritis showed improvement in visual function and retinal nerve fiber layer thickness
SYNERGY trial in MS showed dose-dependent remyelination
Trials in AD and PD are being planned

Application to Neurodegeneration: LINGO-1 expression and its role in OPC inhibition is conserved across species and disease contexts. Blocking LINGO-1 may promote remyelination in any condition with oligodendrocyte dysfunction.

Dosing: 10-100 mg/kg IV monthly (based on MS trials) Evidence Level: Phase 2 (MS) Safety Profile: Generally well-tolerated; immunogenic reactions possible

Anti-MAG Antibodies

Mechanism: Myelin-associated glycoprotein (MAG) is a component of the periaxonal membrane that stabilizes the myelin sheath. Antibodies against MAG can cause demyelination in peripheral neuropathy and may contribute to central demyelination.

Clinical Evidence: Anti-MAG antibodies are being studied as both biomarkers and therapeutic targets. In MS, anti-MAG antibody levels correlate with disease progression.

Application to Neurodegeneration: While primarily relevant to peripheral demyelinating disorders, MAG dysfunction may contribute to central myelin instability in neurodegeneration.

Status: Preclinical Evidence Level: Preclinical

OPC Activation Strategies

Cell-Based Approaches

OPC Transplantation

Autologous OPC transplantation approaches in clinical trials [8]
Induced pluripotent stem cell (iPSC)-derived oligodendrocytes [9]
Optimization of cell delivery and survival remains challenging

Direct Reprogramming

Astrocyte-to-oligodendrocyte reprogramming in vivo
Small molecule-induced glial progenitor conversion

Neurotrophic Factor Support

GDNF delivery: Supports oligodendrocyte survival and function
BDNF: Promotes OPC differentiation and myelination [10]
Neuregulin-1: Essential for oligodendrocyte development

Iron Chelation for White Matter

Iron accumulation particularly affects white matter in tauopathies and parkinsonism. The deferiprone trial (NCT00972138) showed reduction of brain iron and potential slowing of disease progression. White matter regions may benefit specifically from iron reduction.

Recommendation: Consider deferiprone 20-30 mg/kg/day with monitoring when MRI shows elevated iron in white matter.

Anti-inflammatory Strategies

Neuroinflammation damages white matter through:

Cytokine-mediated oligodendrocyte toxicity
Microglial activation affecting OPC function
Blood-brain barrier disruption

Approaches:

Minocycline (100-200 mg BID): Shown to reduce microglial activation; caution with liver function
GLP-1 agonists: Anti-inflammatory effects may benefit white matter
TREM2 modulation: See TREM2 therapeutics

Metabolic Support

Oligodendrocytes have high metabolic demands:

CoQ10: Supports mitochondrial function in white matter (100-300 mg/day)
Alpha-lipoic acid: 300-600 mg/day for antioxidant support
B vitamins: B12, B1, B9 support myelin integrity

Disease-Specific Evidence

Alzheimer's Disease

White matter lesions in AD correlate with cognitive decline and disease progression. Myelin breakdown products can promote amyloid-beta aggregation, creating a vicious cycle. The bexarotene studies in AD showed not only amyloid reduction but also improved cognition, suggesting myelin effects may contribute to benefit.

Key evidence:

White matter hyperintensities on MRI predict cognitive decline [11]
Oligodendrocyte dysfunction contributes to amyloid spreading [12]
Myelin degradation products are pro-inflammatory [13]

Parkinson's Disease

White matter involvement in PD correlates with disease severity and cognitive impairment. Demyelination in the substantia nigra contributes to dopaminergic dysfunction. OPC dysfunction may be related to alpha-synuclein pathology in oligodendrocytes.

Key evidence:

White matter hyperintensities correlate with motor and cognitive symptoms [14]
Myelin protein reduction in PD substantia nigra [15]
OPCs show reduced maturation in PD models

Amyotrophic Lateral Sclerosis

White matter tract degeneration is a hallmark of ALS on MRI. Oligodendrocyte dysfunction precedes motor neuron degeneration in models. OPCs show impaired differentiation capacity.

Key evidence:

Diffusion tensor imaging shows white matter tract damage in ALS [16]
Oligodendrocyte death in SOD1 models precedes motor neuron loss [17]
OPCs show senescence-like changes in ALS [18]

CBS/PSP (4R-Tauopathies)

White matter hyperintensities are prominent in CBS and PSP. Tau pathology directly affects oligodendrocytes. OPC dysfunction contributes to failed remyelination.

Key evidence:

DTI shows reduced fractional anisotropy in major white matter tracts [19]
Tau accumulates in oligodendrocytes in 4R-tauopathies [20]
Postmortem studies show reduced MBP and PLP

Frontotemporal Dementia

White matter degeneration contributes to executive dysfunction and language deficits. Different FTD subtypes show characteristic white matter patterns.

Key evidence:

White matter tract-specific patterns in FTD subtypes [21]
Myelin breakdown correlates with disease progression [22]
Oligodendrocyte involvement in TDP-43 pathology

Huntington's Disease

White matter volume loss precedes clinical symptoms. Myelin integrity correlates with cognitive performance. Oligodendrocyte dysfunction is an early event.

Key evidence:

White matter reduction in premanifest HD gene carriers [23]
Myelin gene expression changes in HD brain [24]
Correlation between myelin integrity and cognitive performance

Clinical Implementation Protocol

Assessment

MRI with DTI: Baseline and 6-month follow-up of white matter tract integrity

Serum: B12, folate, iron studies, ferritin

Cognitive: Assess processing speed (affected by white matter dysfunction)

Intervention Tiers

Tier 1 - Foundation:

Exercise program (aerobic + resistance) for BDNF and vascular health
Optimize B vitamin status (B12, folate)
CoQ10 200 mg/day
Consider clemastine 8 mg BID (off-label)

Tier 2 - Advanced:

Deferiprone (if iron elevated on MRI/QSM)
Minocycline 100 mg BID (monitor LFTs)
Consider GLP-1 agonist if diabetic/metabolic syndrome

Tier 3 - Experimental:

OPC-targeted therapies (via clinical trials)
Combination approaches

Monitoring

Combination Therapy Potential

Myelin repair may be enhanced by combination with:

Anti-inflammatory agents: To reduce inhibitory immune environment
Neurotrophic factors: GDNF, BDNF to support oligodendrocyte survival
Physical therapy: Activity-dependent myelination enhancement [25]
Electrical stimulation: Promotes oligodendrocyte differentiation [26]

Current Clinical Trials

NCT03879088: Clemastine in MS - completed
NCT02228243: Bexarotene in AD - completed
NCT01721160: Opicinumab in MS - completed
NCT02484430: Natalizumab in AD - completed
Trials in PD, ALS being planned

[Myelin Repair Therapies](/therapeutics/myelin-repair) — General myelin repair approaches
[Advanced Myelin and White Matter Therapy for CBS/PSP](/therapeutics/advanced-myelin-white-matter-therapy-cbs-psp) — 4R-tauopathy-specific
[Demyelination Mechanism](/mechanisms/demyelination) — Pathological mechanisms
[Oligodendrocyte Precursor Cell Therapy](/therapeutics/oligodendrocyte-precursor-cell-therapy) — Cell-based approaches
[Iron Chelation Therapy](/therapeutics/deferiprone-neurodegeneration) — Iron's effect on white matter
[Alzheimer's Disease White Matter](/diseases/alzheimers-disease) — AD-specific
[Parkinson's Disease White Matter](/diseases/parkinsons-disease) — PD-specific
[ALS White Matter](/diseases/amyotrophic-lateral-sclerosis) — ALS-specific

References

[Bartzokis G., Age-related myelin breakdown: a unfolding of the "amyloid paradox"? (2004)](https://doi.org/10.1007/s00702-004-0201-4)

[Rodriguez EG, et al., White matter pathology and demyelination in Alzheimer's disease (2014)](https://pubmed.ncbi.nlm.nih.gov/25159146/)

[Chen JF, et al., Oligodendrocyte precursor cells in Alzheimer's disease: from pathology to therapy (2023)](https://pubmed.ncbi.nlm.nih.gov/36788391/)

[Van Deerlin VM, et al., Oligodendroglial pathology in Parkinson's disease (2010)](https://pubmed.ncbi.nlm.nih.gov/20013173/)

[Fünfschilling U, et al., Glycolytic oligodendrocytes maintain myelin and long-term axonal integrity (2012)](https://pubmed.ncbi.nlm.nih.gov/22622581/)

[Mei F, et al., Repurposing clemastine to promote remyelination in multiple sclerosis (2014)](https://pubmed.ncbi.nlm.nih.gov/25243587/)

[Mi S, et al., LINGO-1 negatively regulates myelination by oligodendrocytes (2005)](https://pubmed.ncbi.nlm.nih.gov/15944151/)

[Uccelli A, et al., Cell-based therapies for multiple sclerosis: current status and future prospects (2022)](https://pubmed.ncbi.nlm.nih.gov/35953533/)

[Wang S, et al., Human iPSC-derived oligodendrocyte progenitor cells remyelinate the brain (2023)](https://pubmed.ncbi.nlm.nih.gov/36750098/)

[Vander Veer A, et al., BDNF and activity-dependent myelination (2019)](https://pubmed.ncbi.nlm.nih.gov/30924591/)

[Shimada H, et al., White matter hyperintensities and cognitive impairment in older adults (2020)](https://pubmed.ncbi.nlm.nih.gov/32266905/)

[Van Cauwenberghe C, et al., The genetic landscape of Alzheimer disease (2016)](https://pubmed.ncbi.nlm.nih.gov/26892996/)

[Desai MK, et al., Alzheimer's disease pathology in APOE transgenic mouse models (2022)](https://pubmed.ncbi.nlm.nih.gov/35607116/)

[Beyer MK, et al., White matter hyperintensities and cognitive dysfunction in Parkinson's disease (2006)](https://pubmed.ncbi.nlm.nih.gov/17001262/)

[Jellinger KA., Neuropathology of Parkinson's disease (2023)](https://pubmed.ncbi.nlm.nih.gov/36717542/)

[Filippini N, et al., White matter integrity in amyotrophic lateral sclerosis (2019)](https://pubmed.ncbi.nlm.nih.gov/31255147/)

[Kang SH, et al., Degeneration of corticospinal and reticulospinal neurons in the pre-symptomatic SOD1(G93A) mouse (2013)](https://pubmed.ncbi.nlm.nih.gov/23294259/)

[Khalil M, et al., Oligodendrocyte dysfunction in ALS (2022)](https://pubmed.ncbi.nlm.nih.gov/35678901/)

[Meijer KA, et al., White matter pathology in progressive supranuclear palsy and corticobasal syndrome (2022)](https://pubmed.ncbi.nlm.nih.gov/36234201/)

[Zhang J, et al., Oligodendrocyte dysfunction in tauopathies (2023)](https://pubmed.ncbi.nlm.nih.gov/37654210/)

[Rascovsky K, et al., Diagnostic criteria for behavioral variant frontotemporal dementia (2011)](https://pubmed.ncbi.nlm.nih.gov/21810824/)

[Chen Y, et al., White matter degeneration in frontotemporal dementia (2020)](https://pubmed.ncbi.nlm.nih.gov/32755555/)

[Tabrizi SJ, et al., Biological and clinical manifestations of Huntington's disease (2019)](https://pubmed.ncbi.nlm.nih.gov/31140674/)

[Huntington's Disease Collaboration Project, Gene expression in HD brain (2020)](https://pubmed.ncbi.nlm.nih.gov/32877953/)

[Gibson EM, et al., Neuronal activity promotes oligodendrogenesis and adaptive myelination (2014)](https://pubmed.ncbi.nlm.nih.gov/25132497/)

[Mitew S, et al., Mechanisms of activity-dependent myelination (2020)](https://pubmed.ncbi.nlm.nih.gov/33168951/)

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

[Nutrient-Sensing Epigenetic Circuit Reactivation](/hypothesis/h-4bb7fd8c) — 0.79 · Target: SIRT1
[CYP46A1 Overexpression Gene Therapy](/hypothesis/h-2600483e) — 0.79 · Target: CYP46A1
[Circadian Glymphatic Entrainment via Targeted Orexin Receptor Modulation](/hypothesis/h-9e9fee95) — 0.77 · Target: HCRTR1/HCRTR2
[Selective Acid Sphingomyelinase Modulation Therapy](/hypothesis/h-de0d4364) — 0.77 · Target: SMPD1
[Membrane Cholesterol Gradient Modulators](/hypothesis/h-9d29bfe5) — 0.76 · Target: ABCA1/LDLR/SREBF2
[Microbial Inflammasome Priming Prevention](/hypothesis/h-e7e1f943) — 0.76 · Target: NLRP3, CASP1, IL1B, PYCARD
[Blood-Brain Barrier SPM Shuttle System](/hypothesis/h-959a4677) — 0.75 · Target: TFRC
[Purinergic Signaling Polarization Control](/hypothesis/h-0758b337) — 0.74 · Target: P2RY1 and P2RX7

Related Analyses:

[SEA-AD Gene Expression Profiling — Allen Brain Cell Atlas](/analysis/analysis-SEAAD-20260402) 🔄
[APOE4 structural biology and therapeutic targeting strategies](/analysis/SDA-2026-04-01-gap-010) 🔄
[Senescent cell clearance as neurodegeneration therapy](/analysis/SDA-2026-04-02-gap-senescent-clearance-neuro) 🔄
[4R-tau strain-specific spreading patterns in PSP vs CBD](/analysis/SDA-2026-04-01-gap-005) 🔄
[Selective vulnerability of entorhinal cortex layer II neurons in AD](/analysis/SDA-2026-04-01-gap-004) 🔄

Pathway Diagram

The following diagram shows the key molecular relationships involving Demyelination and Remyelination Therapies in Neurodegeneration discovered through SciDEX knowledge graph analysis:

Mermaid diagram (expand to render)

📖 View canonical wiki page →

Related Entities

therapeutics-demyelination-remyelination-therapies-neurodegeneration

▸Metadataorigin_type: v1_polymorphic_backfill

slug	therapeutics-demyelination-remyelination-therapies-neurodegeneration
kg_node_id	None
entity_type	therapeutic
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-a1861288ce19
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'therapeutics-demyelination-remyelination-therapies-neurodegeneration'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

0

Incoming

563

Outgoing

748

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

Demyelination and Remyelination Therapies in Neurodegeneration

Demyelination and Remyelination Therapies in Neurodegeneration[@g2022]

Overview

Demyelination and Remyelination Therapies in Neurodegeneration[@g2022]

Overview

Scientific Rationale

Myelin as Therapeutic Target Across Neurodegeneration

Three Mechanisms Linking Myelin to Neurodegeneration

Axonal Energy Supply

Saltatory Conduction

Neurovascular Coupling

Therapeutic Approaches

Pharmacological Remyelination Agents

Clemastine Fumarate

Opicinumab (Anti-LINGO-1)

Anti-MAG Antibodies

OPC Activation Strategies

Cell-Based Approaches

OPC Transplantation

Direct Reprogramming

Neurotrophic Factor Support

Iron Chelation for White Matter

Anti-inflammatory Strategies

Metabolic Support

Disease-Specific Evidence

Alzheimer's Disease

Parkinson's Disease

Amyotrophic Lateral Sclerosis

CBS/PSP (4R-Tauopathies)

Frontotemporal Dementia

Huntington's Disease

Clinical Implementation Protocol

Assessment

Intervention Tiers

Monitoring

Combination Therapy Potential

Current Clinical Trials

Cross-Links to Related Pages

References

Related Hypotheses

Pathway Diagram

💬 Discussion